SAKARTA, together with our collaborators in Scotland and Japan, are aiming to revolutionise the regenerative medicine field. The potential of cell therapies to radically change the treatment of degenerative diseases is being held back by high manufacturing costs. This is because manufacturing requires high level HVAC (Heating, Ventilation and Air Conditioning) facilities, combined with large numbers of highly trained staff and can take from 3-8 weeks for production of each batch. SAKARTA will overhall outdated production methods by delivery of an automated system that takes cells from starter culture, all the way to harvested cellular therapy, in a fully automated manner, and within a lower level air handling facility.
This is achieved through the continuous automated monitoring of cell viability/density, differentiation status of the cells and quality of the output in real time. Hence, there is less batch to batch variation and greater output of high quality product.
SAKARTA is building a team of dedicated, entrepreneurial individuals driven by our desire to lower the cost of developing new stem-cell based treatments for degenerative diseases and thus make regenerative medicine a reality for everyone. If you are interested in working in an innovative, dynamic environment, and share our passion for ‘making a difference’ – we would be delighted to meet with you.